JP2023545274A5 - - Google Patents
Info
- Publication number
- JP2023545274A5 JP2023545274A5 JP2023521512A JP2023521512A JP2023545274A5 JP 2023545274 A5 JP2023545274 A5 JP 2023545274A5 JP 2023521512 A JP2023521512 A JP 2023521512A JP 2023521512 A JP2023521512 A JP 2023521512A JP 2023545274 A5 JP2023545274 A5 JP 2023545274A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- dione
- dioxopiperidine
- amino
- isoindoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020119834 | 2020-10-07 | ||
| CNPCT/CN2020/119834 | 2020-10-07 | ||
| PCT/CN2021/122530 WO2022073469A1 (en) | 2020-10-07 | 2021-10-07 | Compounds and methods of treating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545274A JP2023545274A (ja) | 2023-10-27 |
| JP2023545274A5 true JP2023545274A5 (enExample) | 2024-10-16 |
Family
ID=81125595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521512A Pending JP2023545274A (ja) | 2020-10-07 | 2021-10-07 | 癌を処置する化合物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240050428A1 (enExample) |
| EP (1) | EP4225749A4 (enExample) |
| JP (1) | JP2023545274A (enExample) |
| CN (1) | CN116583509A (enExample) |
| WO (1) | WO2022073469A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| AU2022356017B2 (en) * | 2021-10-01 | 2024-05-30 | Nextgen Bioscience Co., Ltd. | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same |
| WO2023193760A1 (en) * | 2022-04-06 | 2023-10-12 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
| CN119630654A (zh) * | 2022-06-10 | 2025-03-14 | 珠海宇繁生物科技有限责任公司 | 蛋白质降解剂及其用途 |
| WO2024015855A1 (en) * | 2022-07-13 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS |
| US20260028326A1 (en) * | 2022-08-10 | 2026-01-29 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Compound based on isoindoline-substituted glutarimide backbone and use thereof |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| WO2024099441A1 (en) * | 2022-11-11 | 2024-05-16 | Jingrui Biopharma (Shandong) Co., Ltd. | Bromodomain and extra-terminal (bet) protein degrader |
| US20240247001A1 (en) | 2022-12-16 | 2024-07-25 | Astrazeneca Ab | 2,6,9-trisubstituted purines |
| WO2024193641A1 (zh) * | 2023-03-21 | 2024-09-26 | 上海超阳药业有限公司 | 异吲哚啉衍生物和苯并吲哚衍生物及其应用 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
| WO2025231420A1 (en) * | 2024-05-03 | 2025-11-06 | Albert Einstein College Of Medicine | Small molecule degraders of soluble epoxide hydrolase |
| WO2026021557A1 (zh) * | 2024-07-26 | 2026-01-29 | 上海超阳药业有限公司 | 苯并吲哚衍生物的药物组合物、制备方法及用途 |
| CN119059953A (zh) * | 2024-08-27 | 2024-12-03 | 吉林大学 | 一种快捷合成1-(乙基磺酰基)氮杂环丁烷-3-酮的方法 |
| WO2026061491A1 (zh) * | 2024-09-20 | 2026-03-26 | 上海超阳药业有限公司 | 一种苯并吲哚衍生物的晶型、盐型及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6684907B2 (ja) * | 2016-07-11 | 2020-04-22 | オリンパス株式会社 | 内視鏡用クリップ装置 |
| US10040804B2 (en) * | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10406165B2 (en) * | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| KR20200020899A (ko) * | 2017-06-30 | 2020-02-26 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법 |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN109422753B (zh) * | 2017-09-03 | 2021-12-31 | 上海美志医药科技有限公司 | 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物 |
| CA3085645C (en) * | 2017-12-13 | 2024-01-16 | Shanghaitech University | Alk protein degraders and their use in cancer therapy |
| CA3101338A1 (en) * | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
| WO2019241271A1 (en) * | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Fused thiophene compounds |
| JP7472103B2 (ja) * | 2018-08-22 | 2024-04-22 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| JP2022533260A (ja) * | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
| WO2021069705A1 (en) * | 2019-10-09 | 2021-04-15 | Monte Rosa Therapeutics | Isoindolinone compounds |
-
2021
- 2021-10-07 JP JP2023521512A patent/JP2023545274A/ja active Pending
- 2021-10-07 WO PCT/CN2021/122530 patent/WO2022073469A1/en not_active Ceased
- 2021-10-07 US US18/248,035 patent/US20240050428A1/en active Pending
- 2021-10-07 CN CN202180082392.9A patent/CN116583509A/zh active Pending
- 2021-10-07 EP EP21876987.5A patent/EP4225749A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023545274A5 (enExample) | ||
| CN103124729B (zh) | 作为Axl抑制剂的药物活性化合物 | |
| AU766081B2 (en) | Phthalazine derivatives for treating inflammatory diseases | |
| CN105473581B (zh) | 作为溴结构域抑制剂的新取代的双环化合物 | |
| JP4516690B2 (ja) | 血管形成阻害活性を有するイソキノリン誘導体 | |
| JP2020521740A5 (enExample) | ||
| JP4092203B2 (ja) | 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法 | |
| JP2004521087A5 (enExample) | ||
| WO2014080290A2 (en) | Cyclic amines as bromodomain inhibitors | |
| CN102812006A (zh) | 新型抗疟疾试剂 | |
| JP2011521968A5 (enExample) | ||
| JP2015503504A (ja) | ヘテロアリールおよびその使用 | |
| CN103025731A (zh) | 作为alk5和/或alk4抑制剂的2-吡啶基取代的咪唑 | |
| WO2005009971A1 (ja) | キノロン誘導体又はその塩 | |
| TW200400032A (en) | Quinoline derivatives (n) as NPY antagonists | |
| TW200925154A (en) | Phenylacetic acid compound | |
| JP2006507355A5 (enExample) | ||
| WO2004029049A1 (ja) | 2-アシルアミノチアゾール誘導体の新規な塩 | |
| CN113354585A (zh) | 新型ep4拮抗剂的合成及其在癌症和炎症中的用途 | |
| JP2020535172A5 (enExample) | ||
| TW200927127A (en) | Agent for overcoming resistance to anti-cancer agent | |
| CN121013856A (zh) | Egfr降解剂、其药物组合物及其用途 | |
| CN102464652B (zh) | 咪唑衍生物、制备方法及用途 | |
| JP6689887B2 (ja) | 新規アミドヘテロアリールアロイルヒドラジドエチン | |
| US20040097539A1 (en) | Hsp inductor |